Outcomes
enterochromaffin-like-cell hyperplasia, foveolar hyperplasia, gastritis, neutrophilic, atrophy
RECURRENCE, INFILTRATION, EROSIVE OESOPHAGITIS, ADVERSE EVENTS, GASTRITIS, INFLAMMATION, INTESTINAL METAPLASIA, BLACK SPOTS, ATROPHY
The primary endpoint was histopathological evaluation of the gastric mucosa, specifically, the presence or absence of neoplastic/dysplastic alteration of epithelial cells, parietal cell protrusion/hyperplasia, foveolar hyperplasia, enterochromaffin-like-cell hyperplasia (endocrine cell micronest; ECM) [Secondary efficacy endpoints were endoscopic erosive oesophagitis healing rate at the end of the healing phase and erosive oesophagitis recurrence rate (recurrence was defined as LA Classification Grades A to D during the maintenance phase). Secondary safety endpoints were incidence of adverse events (AEs), endoscopic findings (presence or absence of fundic gland polyp, hyperplastic polyp, cobblestone mucosa, multiple white flat elevated lesions, and black spots), histological evaluation of gastritis according to the Sydney classification (inflammation [mononuclear infiltration], activity [neutrophilic infiltration], atrophy, intestinal metaplasia, Additional endpoints included serum gastrin level, pepsinogen I and II levels, pepsinogen I/II ratio, and serum chromogranin A level.